These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 15948861)

  • 1. Open prospective multicenter study of conversion to tacrolimus therapy in renal transplant patients experiencing ciclosporin-related side-effects.
    Margreiter R; Pohanka E; Sparacino V; Sperschneider H; Kunzendorf U; Huber W; Lameire N; Andreucci VE; Donati D; Heemann U;
    Transpl Int; 2005 Jul; 18(7):816-23. PubMed ID: 15948861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conversion to tacrolimus once-daily from ciclosporin in stable kidney transplant recipients: a multicenter study.
    Rostaing L; Sánchez-Fructuoso A; Franco A; Glyda M; Kuypers DR; Jaray J
    Transpl Int; 2012 Apr; 25(4):391-400. PubMed ID: 22211928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved attainment of NKF classified lipid target levels after conversion from cyclosporine to tacrolimus in renal graft recipients.
    Pohanka E; Margreiter R; Sparacino V; Sperschneider H;
    Transplant Proc; 2005 May; 37(4):1874-6. PubMed ID: 15919490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improvement of cardiovascular risk factors and cosmetic side effects in kidney transplant recipients after conversion to tacrolimus.
    Zadrazil J; Horak P; Zahalkova J; Strebl P; Horcicka V; Krejci K; Bachleda P; Dedochova J; Valkovsky I
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2009 Mar; 153(1):67-73. PubMed ID: 19365530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Hypertrichosis and gingival hypertrophy regression in renal transplants following the substitution of cyclosporin by tacrolimus].
    Busque S; Demers P; Saint-Louis G; Boily JG; Tousignant J; Lemieux F; Martin G; Smeesters C; Corman J; Daloze P
    Ann Chir; 1999; 53(8):687-9. PubMed ID: 10584376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal function and cardiovascular risk profile after conversion from ciclosporin to tacrolimus: prospective study in 80 liver transplant recipients.
    Beckebaum S; Klein C; Varghese J; Sotiropoulos GC; Saner F; Schmitz K; Gerken G; Paul A; Cicinnati VR
    Aliment Pharmacol Ther; 2009 Oct; 30(8):834-42. PubMed ID: 19624550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tacrolimus conversion improves hyperlipidemic states in stable liver transplant recipients.
    Manzarbeitia C; Reich DJ; Rothstein KD; Braitman LE; Levin S; Munoz SJ
    Liver Transpl; 2001 Feb; 7(2):93-9. PubMed ID: 11172391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Steroid-free immunosuppression in kidney transplant recipients and prograf monotherapy: an interim analysis of a prospective multicenter trial.
    Bäckman L; Aselius H; Lindberger K; Svensson L; Strömbom U; Olausson E; Hadimeri H; Deurell SI; Norrby J; Gäbel M; Ebermark A; Olausson M
    Transplant Proc; 2006 Oct; 38(8):2654-6. PubMed ID: 17098029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Switching from cyclosporine to tacrolimus leads to improved disease-specific quality of life in patients after kidney transplantation.
    Franke GH; Trampenau C; Reimer J;
    Transplant Proc; 2006 Jun; 38(5):1293-4. PubMed ID: 16797285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conversion from cyclosporine microemulsion to tacrolimus in stable kidney transplant patients with hypercholesterolemia is related to an improvement in cardiovascular risk profile: a prospective study.
    Marcén R; Chahin J; Alarcón A; Bravo J
    Transplant Proc; 2006 Oct; 38(8):2427-30. PubMed ID: 17097957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conversion from Neoral (cyclosporine) to tacrolimus of kidney transplant recipients for gingival hyperplasia or hypertrichosis.
    Busque S; Demers P; St-Louis G; Boily JG; Tousignant J; Lemieux F; Smeesters C; Corman J; Daloze P
    Transplant Proc; 1998 Jun; 30(4):1247-8. PubMed ID: 9636507
    [No Abstract]   [Full Text] [Related]  

  • 12. [Effect of cyclosporin and tacrolimus on lipoprotein oxidation after renal transplantation].
    Martínez Castelao A; Ramos R; Serón D; Gil-Vernet S; Fiol C; Gómez-Gerique N; Yzaguirre MT; Hurtado I; Sabaté I; Alsina J; Grinyó JM
    Nefrologia; 2002; 22(4):364-9. PubMed ID: 12369128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.
    Yu S; He X; Yang L; Ma Y; Zhu X; Ju W; Huang J
    Exp Clin Transplant; 2008 Jun; 6(2):113-7. PubMed ID: 18816237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conversion to tacrolimus and atorvastatin in cyclosporine-treated heart transplant recipients with dyslipidemia refractory to fluvastatin.
    Skalicka B; Kubanek M; Malek I; Vymetalova Y; Hoskova L; Podzimkova M; Kautzner J
    J Heart Lung Transplant; 2009 Jun; 28(6):598-604. PubMed ID: 19481021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conversion from cyclosporine microemulsion to tacrolimus-based immunoprophylaxis improves cholesterol profile in heart transplant recipients with treated but persistent dyslipidemia: the Canadian multicentre randomized trial of tacrolimus vs cyclosporine microemulsion.
    White M; Haddad H; Leblanc MH; Giannetti N; Pflugfelder P; Davies R; Isaac D; Burton J; Chan M; Azevedo E; Howlett J; Ignaszewski A; Busque S; Cantarovich M; Ferguson R; Genest J; Ross H
    J Heart Lung Transplant; 2005 Jul; 24(7):798-809. PubMed ID: 15982605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conversion of ciclosporin A to tacrolimus in kidney transplant recipients with chronic allograft nephropathy.
    Tang SC; Chan KW; Tang CS; Lam MF; Leung CY; Tse KC; Li CS; Ho YW; Tong MK; Lai KN; Chan TM;
    Nephrol Dial Transplant; 2006 Nov; 21(11):3243-51. PubMed ID: 16877482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. One-year observation of kidney allograft recipients converted from cyclosporine microemulsion to tacrolimus.
    Chamienia A; Biedunkiewicz B; Król E; Debska-Slizień A; Rutkowski B
    Transplant Proc; 2006; 38(1):81-5. PubMed ID: 16504670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus.
    Levy G; Grazi GL; Sanjuan F; Wu Y; Mühlbacher F; Samuel D; Friman S; Jones R; Cantisani G; Villamil F; Cillo U; Clavien PA; Klintmalm G; Otto G; Pollard S; McCormick PA
    Liver Transpl; 2006 Oct; 12(10):1464-72. PubMed ID: 17004259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conversion from cyclosporine to tacrolimus in patients at risk for chronic renal allograft failure: 60-month results of the CRAF Study.
    Shihab FS; Waid TH; Conti DJ; Yang H; Holman MJ; Mulloy LC; Henning AK; Holman J; First MR;
    Transplantation; 2008 May; 85(9):1261-9. PubMed ID: 18475181
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gingival overgrowth in a renal transplant recipient using cyclosporine A.
    Gonçalves SC; Díaz-Serrano KV; de Queiroz AM; Palioto DB; Faria G
    J Dent Child (Chic); 2008; 75(3):313-7. PubMed ID: 19040821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.